Midori Kubota
University of Tokyo
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Midori Kubota.
Journal of Biological Chemistry | 2010
Yoshinori Takeuchi; Naoya Yahagi; Yoshihiko Izumida; Makiko Nishi; Midori Kubota; Yuji Teraoka; Takashi Yamamoto; Takashi Matsuzaka; Yoshimi Nakagawa; Motohiro Sekiya; Yoko Iizuka; Ken Ohashi; Jun Ichi Osuga; Takanari Gotoda; Shun Ishibashi; Keiji Itaka; Kazunori Kataoka; Ryozo Nagai; Nobuhiro Yamada; Takashi Kadowaki; Hitoshi Shimano
Sterol regulatory element-binding protein (SREBP)-1 is a key transcription factor for the regulation of lipogenic enzyme genes in the liver. Polyunsaturated fatty acids (PUFA) selectively suppress hepatic SREBP-1, but molecular mechanisms remain largely unknown. To gain insight into this regulation, we established in vivo reporter assays to assess the activities of Srebf1c transcription and proteolytic processing. Using these in vivo reporter assays, we showed that the primary mechanism for PUFA suppression of SREBP-1 is at the proteolytic processing level and that this suppression in turn decreases the mRNA transcription through lowering SREBP-1 binding to the SREBP-binding element on the promoter (“autoloop regulatory circuit”), although liver X receptor, an activator for Srebf1c transcription, is not involved in this regulation by PUFA. The mechanisms for PUFA suppression of SREBP-1 confirm that the autoloop regulation for transcription is crucial for the nutritional regulation of triglyceride synthesis.
Nature Communications | 2013
Yoshihiko Izumida; Naoya Yahagi; Yoshinori Takeuchi; Makiko Nishi; Akito Shikama; Ayako Takarada; Yukari Masuda; Midori Kubota; Takashi Matsuzaka; Yoshimi Nakagawa; Yoko Iizuka; Keiji Itaka; Kazunori Kataoka; Seiji Shioda; Akira Niijima; Tetsuya Yamada; Hideki Katagiri; Ryozo Nagai; Nobuhiro Yamada; Takashi Kadowaki; Hitoshi Shimano
During fasting, animals maintain their energy balance by shifting their energy source from carbohydrates to triglycerides. However, the trigger for this switch has not yet been entirely elucidated. Here we show that a selective hepatic vagotomy slows the speed of fat consumption by attenuating sympathetic nerve-mediated lipolysis in adipose tissue. Hepatic glycogen pre-loading by the adenoviral overexpression of glycogen synthase or the transcription factor TFE3 abolished this liver–brain–adipose axis activation. Moreover, the blockade of glycolysis through the knockdown of the glycogen phosphorylase gene and the resulting elevation in the glycogen content abolished the lipolytic signal from the liver, indicating that glycogen is the key to triggering this neurocircuitry. These results demonstrate that liver glycogen shortage activates a liver–brain–adipose neural axis that has an important role in switching the fuel source from glycogen to triglycerides under prolonged fasting conditions.
Biochemical and Biophysical Research Communications | 2015
Akito Shikama; Haruna Shinozaki; Yoshinori Takeuchi; Takashi Matsuzaka; Tomoki Murayama; Yoshikazu Sawada; Xiaoying Piao; Naoki Toya; Yukari Oya; Ayako Takarada; Yukari Masuda; Makiko Nishi; Midori Kubota; Yoshihiko Izumida; Yoshimi Nakagawa; Hitoshi Iwasaki; Kazuto Kobayashi; Shigeru Yatoh; Hiroaki Suzuki; Hiroaki Yagyu; Yasushi Kawakami; Nobuhiro Yamada; Hitoshi Shimano; Naoya Yahagi
Fatty acid elongase 5 (ELOVL5) is an enzyme involved in the synthesis of polyunsaturated fatty acids. Sterol Regulatory Element-binding Protein (SREBP)-1 activates ELOVL5 and increases polyunsaturated fatty acid synthesis, which in turn negatively affects SREBP-1 expression. Thus, ELOVL5 has been established as an SREBP-1 target gene and an important component of the negative feedback loop of de novo lipogenesis. However, the human ELOVL5 promoter/enhancer has not been fully analyzed and the location of SREBP biding sites around the ELOVL5 gene has yet to be defined. Here we performed a detailed promoter/enhancer analysis of human ELOVL5 gene, and identified two new SREBP binding sites, one in the 10 kb upstream region and one in the exon 1. These two SRE motifs are conserved among mammals and the mechanism found in the present study by which SREBP activates ELOVL5 is considered to be common in mammals. Through these findings, we clarified the molecular mechanism how SREBP activates ELOVL5, an important regulator of de novo lipogenesis.
Biochemical and Biophysical Research Communications | 2011
Keisuke Ohta; Motohiro Sekiya; Hiroshi Uozaki; Masaki Igarashi; Satoru Takase; Masayoshi Kumagai; Mikio Takanashi; Yoshinori Takeuchi; Yoshihiko Izumida; Midori Kubota; Makiko Nishi; Hiroaki Okazaki; Yoko Iizuka; Naoya Yahagi; Hiroaki Yagyu; Masashi Fukayama; Takashi Kadowaki; Ken Ohashi; Shun Ishibashi; Jun-ichi Osuga
We have previously demonstrated that neutral cholesterol ester hydrolase 1 (Nceh1) regulates foam cell formation and atherogenesis through the catalytic activity of cholesterol ester hydrolysis, and that Nceh1 and hormone-sensitive lipase (Lipe) are responsible for the majority of neutral cholesterol ester hydrolase activity in macrophages. There are several cholesterol ester-metabolizing tissues and cells other than macrophages, among which adrenocortical cells are also known to utilize the intracellular cholesterol for steroidogenesis. It has been believed that the mobilization of intracellular cholesterol ester in adrenal glands was facilitated solely by Lipe. We herein demonstrate that Nceh1 is also involved in cholesterol ester hydrolysis in adrenal glands. While Lipe deficiency remarkably reduced the neutral cholesterol ester hydrolase activity in adrenal glands as previously reported, additional inactivation of Nceh1 gene completely abrogated the activity. Adrenal glands were enlarged in proportion to the degree of reduced neutral cholesterol ester hydrolase activity, and the enlargement of adrenal glands and the accumulation of cholesterol esters were most pronounced in the Nceh1/Lipe double-deficient mice. Thus Nceh1 is involved in the adrenal cholesterol metabolism, and the cholesterol ester hydrolytic activity in adrenal glands is associated with the organ enlargement.
Biochemical and Biophysical Research Communications | 2009
Motohiro Sekiya; Naoya Yahagi; Yoshiaki Tamura; Hiroaki Okazaki; Masaki Igarashi; Keisuke Ohta; Mikio Takanashi; Masayoshi Kumagai; Satoru Takase; Makiko Nishi; Yoshinori Takeuchi; Yoshihiko Izumida; Midori Kubota; Ken Ohashi; Yoko Iizuka; Hiroaki Yagyu; Takanari Gotoda; Ryozo Nagai; Hitoshi Shimano; Nobuhiro Yamada; Takashi Kadowaki; Shun Ishibashi; Jun-ichi Osuga
It has long been a matter of debate whether the hormone-sensitive lipase (HSL)-mediated lipolysis in pancreatic beta-cells can affect insulin secretion through the alteration of lipotoxicity. We generated mice lacking both leptin and HSL Lep(ob/ob)/HSL(-/-) and explored the role of HSL in pancreatic beta-cells in the setting of obesity. Lep(ob/ob)/HSL(-/-) developed elevated blood glucose levels and reduced plasma insulin levels compared with Lep(ob/ob)/HSL(+/+) in a fed state, while the deficiency of HSL did not affect glucose homeostasis in Lep(+/+) background. The deficiency of HSL exacerbated the accumulation of triglycerides in Lep(ob/ob) islets, leading to reduced glucose-stimulated insulin secretion. The deficiency of HSL also diminished the islet mass in Lep(ob/ob) mice due to decreased cell proliferation. In conclusion, HSL affects insulin secretary capacity especially in the setting of obesity.
FEBS Letters | 2017
Makiko Nishi-Tatsumi; Naoya Yahagi; Yoshinori Takeuchi; Naoki Toya; Ayako Takarada; Yuki Murayama; Yoshikazu Sawada; Xiaoying Piao; Yukari Oya; Akito Shikama; Yukari Masuda; Midori Kubota; Yoshihiko Izumida; Takashi Matsuzaka; Yoshimi Nakagawa; Motohiro Sekiya; Yoko Iizuka; Yasushi Kawakami; Takashi Kadowaki; Nobuhiro Yamada; Hitoshi Shimano
Fatty acid synthase (Fasn) is a key component of energy metabolism that is dynamically induced by food intake. Although extensive studies have revealed a number of transcription factors involved in the fasting/refeeding transition of Fasn expression in hepatocytes, much less evidence is available for adipocytes. Using the in vivo Ad‐luc analytical system, we identified the inverted CCAAT element (ICE) around −100 nucleotides in the Fasn promoter as a critical cis‐element for the refeeding response in adipocytes. Electrophoretic mobility shift assays and chromatin immunoprecipitation show that nuclear factor Y (NF‐Y) binds to ICE specifically in refeeding states. Notably, the NF‐Y binding to ICE is differently regulated between adipocytes and hepatocytes. These findings provide insights into the specific mechanisms controlling energy metabolism in adipocytes.
Biochemical and Biophysical Research Communications | 2017
Yoshikazu Sawada; Yoshihiko Izumida; Yoshinori Takeuchi; Nobuhiro Wada; EnXu Li; Yuki Murayama; Xianying Piao; Akito Shikama; Yukari Masuda; Makiko Nishi-Tatsumi; Midori Kubota; Motohiro Sekiya; Takashi Matsuzaka; Yoshimi Nakagawa; Yoko Sugano; Hitoshi Iwasaki; Kazuto Kobayashi; Shigeru Yatoh; Hiroaki Suzuki; Hiroaki Yagyu; Yasushi Kawakami; Takashi Kadowaki; Hitoshi Shimano; Naoya Yahagi
Sodium-glucose cotransporter 2 (SGLT2) inhibitors have both anti-diabetic and anti-obesity effects. However, the precise mechanism of the anti-obesity effect remains unclear. We previously demonstrated that the glycogen depletion signal triggers lipolysis in adipose tissue via liver-brain-adipose neurocircuitry. In this study, therefore, we investigated whether the anti-obesity mechanism of SGLT2 inhibitor is mediated by this mechanism. Diet-induced obese mice were subjected to hepatic vagotomy (HVx) or sham operation and loaded with high fat diet containing 0.015% tofogliflozin (TOFO), a highly selective SGLT2 inhibitor, for 3 weeks. TOFO-treated mice showed a decrease in fat mass and the effect of TOFO was attenuated in HVx group. Although both HVx and sham mice showed a similar level of reduction in hepatic glycogen by TOFO treatment, HVx mice exhibited an attenuated response in protein phosphorylation by protein kinase A (PKA) in white adipose tissue compared with the sham group. As PKA pathway is known to act as an effector of the liver-brain-adipose axis and activate triglyceride lipases in adipocytes, these results indicated that SGLT2 inhibition triggered glycogen depletion signal and actuated liver-brain-adipose axis, resulting in PKA activation in adipocytes. Taken together, it was concluded that the effect of SGLT2 inhibition on weight loss is in part mediated via the liver-brain-adipose neurocircuitry.
FEBS Letters | 2018
Xianying Piao; Naoya Yahagi; Yoshinori Takeuchi; Yuki Murayama; Yoshikazu Sawada; Akito Shikama; Yukari Masuda; Makiko Nishi-Tatsumi; Midori Kubota; Yoshihiko Izumida; Motohiro Sekiya; Takashi Matsuzaka; Yoshimi Nakagawa; Yoko Sugano; Hitoshi Iwasaki; Kazuto Kobayashi; Shigeru Yatoh; Hiroaki Suzuki; Hiroaki Yagyu; Yasushi Kawakami; Hitoshi Shimano
The SNP rs7903146 at the transcription factor 7‐like 2 (TCF7L2) locus is established as the strongest known genetic marker for type 2 diabetes via genome‐wide association studies. However, the functional SNPs regulating TCF7L2 expression remain unclear. Here, we show that the SNP rs7074440 is a candidate functional SNP highly linked with rs7903146. A reporter plasmid with rs7074440 normal allele sequence exhibited 15‐fold higher luciferase activity compared with risk allele sequence in hepatocytes, demonstrating a strong enhancer activity at rs7074440. Additionally, we identified C‐FOS as an activator binding to the rs7074440 enhancer using a TFEL genome‐wide screen method. Consistently, knockdown of C‐FOS significantly reduced TCF7L2 expression in hepatocytes. Collectively, a novel enhancer regulating TCF7L2 expression was revealed through searching for functional SNPs.
Cell Reports | 2016
Yoshinori Takeuchi; Naoya Yahagi; Yuki Murayama; Yoshikazu Sawada; Xiaoying Piao; Naoki Toya; Yukari Oya; Akito Shikama; Ayako Takarada; Yukari Masuda; Makiko Nishi; Midori Kubota; Yoshihiko Izumida; Takashi Yamamoto; Motohiro Sekiya; Takashi Matsuzaka; Yoshimi Nakagawa; Osamu Urayama; Yasushi Kawakami; Yoko Iizuka; Takanari Gotoda; Keiji Itaka; Kazunori Kataoka; Ryozo Nagai; Takashi Kadowaki; Nobuhiro Yamada; Yuan Lu; Mukesh K. Jain; Hitoshi Shimano
Journal of Atherosclerosis and Thrombosis | 2013
Satoru Takase; Jun-ichi Osuga; Hayato Fujita; Kazuo Hara; Motohiro Sekiya; Masaki Igarashi; Mikio Takanashi; Yoshinori Takeuchi; Yoshihiko Izumida; Keisuke Ohta; Masayoshi Kumagai; Makiko Nishi; Midori Kubota; Yukari Masuda; Yoshino Taira; Sachiko Okazaki; Yoko Iizuka; Naoya Yahagi; Ken Ohashi; Hiroshi Yoshida; Hidekatsu Yanai; Norio Tada; Takanari Gotoda; Shun Ishibashi; Takashi Kadowaki; Hiroaki Okazaki